Progenra’s portfolio of novel first in class small molecules includes selective DUB and E3 ligase inhibitors and PROTAC® molecules, and we welcome industry partners to execute mutually beneficial licensing agreements for our small molecule portfolio assets and/or our UbiPro™ Drug Discovery Platform or our PROTACs Platform. Progenra wishes to continue working with academic institutions to further dissect the ubiquitin proteasome system and we welcome discussions with commercial and academic entities focusing on in-licensing technologies and/or compounds that are complementary to our internal development strategy.
Additionally, Progenra’s business development team has worked successfully with a variety of companies and academic institutions to establish agreements that are compatible with our partner’s strategic focus and goals. Overall, Our expert discovery team and external network can provide solutions to any problem in the field.
Partnering with Progenra includes:
- Unparalleled expertise in the ubiquitin proteasome system
- Small molecule (enzyme modulator and PROTAC) drug candidate assets in
- Access to all the tools and technology under Progenra’s UbiPro™ and PROTAC Drug Discovery Platforms on an exclusive or nonexclusive basis to identify and develop a modifier of a deubiquitylase or ligase or a PROTAC molecule for use as a therapeutic
- Development of new targets within the ubiquitin-proteasome system for the identification of modifiers
Research collaboration with Progenra allows Progenra’s partners to overcome the greatest barriers to working in the ubiquitin field.
Please contact the Progenra Business Development Team for enquiries: firstname.lastname@example.org.
PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.